ARCUS BIOSCIENCES, INC. Business Segments Arcus Biosciences, Inc.
Equities
RCUS
US03969F1093
Biotechnology & Medical Research
|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 16.32 USD | +0.03% |
|
-2.53% | -15.45% |
Sales 2023 by Business Segment
Sales 2023 by Geography
Historical Breakdown of Revenue by Business Segments
Net Income: Breakdown by Business Segment
| Fiscal Period: December | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|---|---|
Biological Products | ||||||||
Developing and Commercializing Immunotherapies | 15M | 77.52M | 383M | 112M | 117M | |||
Total Assets | 203M | 772M | 1.59B | 1.34B | 1.1B | |||
Interest Expense | - | - | -260K | -2M | -2M | |||
Income Tax Expense | - | - | 1.82M | 1M | 6M | |||
CAPEX | -1.92M | -3.06M | -26.08M | -12M | -24M | |||
EBT | -84.71M | -123M | 54.64M | -266M | -301M | |||
D&A | 3.58M | 4.19M | 3.84M | 6M | 8M | |||
Operating Income | -88.71M | -124M | 54.25M | -280M | -340M | |||
Net Income | -84.71M | -123M | 52.83M | -267M | -307M |
Geographical Revenue Distribution History
| Fiscal Period: December | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|---|---|
United States | 15M | 77.52M | 383M | 112M | 117M | |||
Total Assets | 203M | 772M | 1.59B | 1.34B | 1.1B | |||
Interest Expense | - | - | -260K | -2M | -2M | |||
Income Tax Expense | - | - | 1.82M | 1M | 6M | |||
D&A | 3.58M | 4.19M | 3.84M | 6M | 8M | |||
CAPEX | -1.92M | -3.06M | -26.08M | -12M | -24M | |||
Net Income | -84.71M | -123M | 52.83M | -267M | -307M | |||
EBT | -84.71M | -123M | 54.64M | -266M | -301M | |||
Operating Income | -88.71M | -124M | 54.25M | -280M | -340M |
- Stock Market
- Equities
- RCUS Stock
- Financials Arcus Biosciences, Inc.
- Business Segments
MarketScreener is also available in this country: United States.
Switch edition